ReviewFrontiers in cellular neuroscience2013
Neuroplasticity and the next wave of antidepressant strategies.
Review in Frontiers in cellular neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm.NeuroImage · 2021Trial
- Trial
- Impact of chronic SSRI administration on memory parameters, lipid components and membrane properties in C57Bl/6J mice.Frontiers in pharmacology · 2026Article
- Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies.Biomedicines · 2024Review
- Pathophysiological basis and promise of experimental therapies for Gulf War Illness, a chronic neuropsychiatric syndrome in veterans.Psychopharmacology · 2023Review
- Depression in Sub-Saharan Africa.IBRO neuroscience reports · 2022Article
- Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders.Frontiers in psychiatry · 2022Review
- Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review).Experimental and therapeutic medicine · 2021Review
- Depression, dementia and immune dysregulation.Brain : a journal of neurology · 2021Article
- Precision Medicine in Alzheimer's Disease: Investigating Comorbid Common Biological Substrates in the Rat Model of Amyloid Beta-Induced Toxicity.Frontiers in pharmacology · 2021Article
- mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.Molecular neurobiology · 2020Article
- Antidepressant Use During Development May Impair Women's Sexual Desire in Adulthood.The journal of sexual medicine · 2020Article
- The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action.Frontiers in pharmacology · 2020Article
- GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?Translational psychiatry · 2018Review
- Psychedelics Promote Structural and Functional Neural Plasticity.Cell reports · 2018Article
- Acute exposure to diesel exhaust impairs adult neurogenesis in mice: prominence in males and protective effect of pioglitazone.Archives of toxicology · 2018Article
- Scale-Up Synthesis and Identification of GLYX-13, a NMDAR Glycine-Site Partial Agonist for the Treatment of Major Depressive Disorder.Molecules (Basel, Switzerland) · 2018Article
- Role and Possible Mechanisms of Sirt1 in Depression.Oxidative medicine and cellular longevity · 2018Review
- From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder.Frontiers in cellular neuroscience · 2017Review
- Mechanisms Underlying the Antidepressant Response of Acupuncture via PKA/CREB Signaling Pathway.Neural plasticity · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a common chronic psychiatric disorder that is also often co-morbid with numerous neurological and immune diseases. Accumulating evidence indicates that disturbances of neuroplasticity occur with depression, including reductions of hippocampal neurogenesis and cortical synaptogenesis. Improper trophic support stemming from stressor-induced reductions of growth factors, most notably brain derived neurotrophic factor (BDNF), likely drives such aberrant neuroplasticity. We posit that psychological and immune stressors can interact upon a vulnerable genetic background to promote depression by disturbing BDNF and neuroplastic processes. Furthermore, the chronic and commonly relapsing nature of depression is suggested to stem from "faulty wiring" of emotional circuits driven by neuroplastic aberrations. The present review considers depression in such terms and attempts to integrate the available evidence indicating that the efficacy of current and "next wave" antidepressant treatments, whether used alone or in combination, is at least partially tied to their ability to modulate neuroplasticity. We particularly focus on the N-methyl-D-aspartate (NMDA) antagonist, ketamine, which already has well documented rapid antidepressant effects, and the trophic cytokine, erythropoietin (EPO), which we propose as a potential adjunctive antidepressant agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.